Next Article in Journal
Induction of Biologically Active Flavonoids in Cell Cultures of Morus nigra and Testing their Hypoglycemic Efficacy
Previous Article in Journal
Study on Cytochrome P-450 Dependent Retinoic Acid Metabolism and its Inhibitors as Potential Agents for Cancer Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sci. Pharm.
Volume 79
Issue 4
10.3797/scipharm.1106-21
scipharm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Quinazolinobenzodiazepine Derivatives, Novobenzomalvins A–C: Fibronectin Expression Regulators from Aspergillus novofumigatus

by
Kazuki ISHIKAWA
1,
Tomoo HOSOE
1,*,
Takeshi ITABASHI
1,
Fumiaki SATO
1,
Hiroshi WACHI
1,
Hiromasa NAGASE
1,
Takashi YAGUCHI
2 and
Ken-Ichi KAWAI
1
1
Faculty of Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan
2
Medical Mycology Research Center, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8673, Japan
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2011, 79(4), 937-950; https://doi.org/10.3797/scipharm.1106-21
Submission received: 25 June 2011 / Accepted: 3 October 2011 / Published: 3 October 2011
Versions Notes

Abstract

Three new quinazolinobenzodiazepine derivatives, novobenzomalvins A (1), B (2), and C (3), have been isolated as fibronectin expression regulators from Aspergillus novofumigatus CBS117520. The structures of 1 to 3 were established by spectroscopic and physicochemical analysis, and chemical investigation including the total synthesis of 1. Treatment with novo-benzomalvins A (1), B (2), C (3), and N-methylnovobenzomalvin A (5) increased the expression of fibronectin in normal human neonatal dermal fibroblast cells.
Keywords: Aspergillus novofumigatus; Novobenzomalvin; Quinazolinobenzodiazepine; Fibronectin expression regulator; Alkaloids; X-ray crystallography Aspergillus novofumigatus; Novobenzomalvin; Quinazolinobenzodiazepine; Fibronectin expression regulator; Alkaloids; X-ray crystallography

Share and Cite

MDPI and ACS Style

ISHIKAWA, K.; HOSOE, T.; ITABASHI, T.; SATO, F.; WACHI, H.; NAGASE, H.; YAGUCHI, T.; KAWAI, K.-I. Quinazolinobenzodiazepine Derivatives, Novobenzomalvins A–C: Fibronectin Expression Regulators from Aspergillus novofumigatus. Sci. Pharm. 2011, 79, 937-950. https://doi.org/10.3797/scipharm.1106-21

AMA Style

ISHIKAWA K, HOSOE T, ITABASHI T, SATO F, WACHI H, NAGASE H, YAGUCHI T, KAWAI K-I. Quinazolinobenzodiazepine Derivatives, Novobenzomalvins A–C: Fibronectin Expression Regulators from Aspergillus novofumigatus. Scientia Pharmaceutica. 2011; 79(4):937-950. https://doi.org/10.3797/scipharm.1106-21

Chicago/Turabian Style

ISHIKAWA, Kazuki, Tomoo HOSOE, Takeshi ITABASHI, Fumiaki SATO, Hiroshi WACHI, Hiromasa NAGASE, Takashi YAGUCHI, and Ken-Ichi KAWAI. 2011. "Quinazolinobenzodiazepine Derivatives, Novobenzomalvins A–C: Fibronectin Expression Regulators from Aspergillus novofumigatus" Scientia Pharmaceutica 79, no. 4: 937-950. https://doi.org/10.3797/scipharm.1106-21

APA Style

ISHIKAWA, K., HOSOE, T., ITABASHI, T., SATO, F., WACHI, H., NAGASE, H., YAGUCHI, T., & KAWAI, K. -I. (2011). Quinazolinobenzodiazepine Derivatives, Novobenzomalvins A–C: Fibronectin Expression Regulators from Aspergillus novofumigatus. Scientia Pharmaceutica, 79(4), 937-950. https://doi.org/10.3797/scipharm.1106-21

Article Metrics

Back to TopTop